Výsledky vyhledávání - "T I Kolosheinova"

Akademický článek

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease

Autor: A L Melikyan, I N Subortseva, A B Sudarikov, A M Kovrigina, E A Gilyazitdinova, T I Kolosheinova, A O Abdullaev, S A Treglazova

Publikováno v: Терапевтический архив, Vol 89, Iss 7, Pp 4-9 (2017)

The aim of the present paper was to evaluate the clinical features and risk of thrombotic events (TE) in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), depending on the molecular characteristics of disease. Clinical dat

Externí odkaz: https://doaj.org/article/fff1484298094c0d95e324ea2cf2b148

Zobrazit plný text záznamu

Akademický článek

Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases

Autor: Anna Grigor'evna Turkina, Elena Vasil'evna Domracheva, Aleksandra Valer'evna Vorontsova, Elena Aleksandrovna Aseeva, Ol'ga Yur'evna Vinogradova, Ol'ga Veniaminovna Stakhina, Galina Anatol'evna Gusarova, Ol'ga Arkad'evna Dyagileva, Elena Aleksandrovna Semenova, Marina Vasil'evna Vakhrusheva, Tamara Ivanovna Kolosheynova, Evgeniy Mikhaylovich Abakumov, Ekaterina Yur'evna Chelysheva, Svetlana Rudol'fovna Goryacheva, Tat'yana Vladimirovna Ivanova, Elena Stanislavovna Zakharova, Lyubov' Yur'evna Kolosova, Adel' Vladimirovna Zakharova, Irina Nikolaevna Naumova, Larisa Vladimirovna Dyachenko, Sergey Mikhaylovich Kulikov, Lidiya Grigor'evna Kovaleva, Nina Dmitrievna Khoroshko, A G Turkina, E V Domracheva, A V Vorontsova, E A Aseeva, O Yu Vinogradova, O V Stakhina, G A Gusarova, O A Dyagileva, E A Semenova, M V Vakhrusheva, T I Kolosheinova, E M Abakumov, E Yu Chelysheva, S R Goryacheva, T V Ivanova, E S Zakharova, L Yu Kolosova, A V Zakharova, I N Naumova, L V Dyachenko, S M Kulikov, L G Kovaleva, N D Khoroshko

Publikováno v: Терапевтический архив, Vol 81, Iss 7, Pp 29-36 (2009)

Aim. To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK). Material and methods. A total of 386 patients with

Externí odkaz: https://doaj.org/article/ede8cfd0b762457a94075ebaf7be705f

Zobrazit plný text záznamu

Akademický článek

Density-specific distribution of erythrocytes in different types of anemia

Autor: E S Shukhrina, V M Nesterenko, S V Kolodey, N V Tsvetaeva, T A Ermakova, O F Nikulina, T I Kolosheynova, F I Ataullakhanov, T I Kolosheinova

Publikováno v: Терапевтический архив, Vol 0, Iss 1, Pp 48-51 (2009)

Aim. To study density-specific distribution of erythrocytes (DSDE) in different types of anemia. Material and methods. DSDE was determined in anemic patients by fractionation of the whole blood in hematocritic capillaries in the presence of mixtures

Externí odkaz: https://doaj.org/article/883c32913de04fa4b376a1009508185e

Zobrazit plný text záznamu

Akademický článek

Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study

Autor: Ye. А. Stadnik, Ye. А. Nikitin, B. V. Biderman, G. N. Salogub, Yu. Yu. Lorie, N. N. Tsyba, Yu. A. Alexeeva, V. A. Doronin, V. N. Mashuk, R. I. Vabishevich, A. L. Melikyan, T. I. Kolosheinova, L. Yu. Kolosova, A. B. Sudarikov, L. G. Kovaleva, A. Yu. Zaritsky

Publikováno v: Онкогематология, Vol 0, Iss 1-2, Pp 39-46 (2022)

Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell ly

Externí odkaz: https://doaj.org/article/00a0c2ea06324c9092c0197da79d94d1

Zobrazit plný text záznamu

Akademický článek

Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy

Publikováno v: Онкогематология, Vol 7, Iss 4, Pp 24-34 (2014)

The additional molecular and chromosomal abnormalities (ACA) in Phositive cells usually considered as a genetic marker of chronic myeloid leukemia (CML) progression. 457 patients in different CML phases received tyrosine kinase inhibitors (1st and 2n

Externí odkaz: https://doaj.org/article/7ea311ab795742f692200cfebd5c35ea

Zobrazit plný text záznamu

Dermatological Toxicity of Hydroxycarbamide

Autor: I N Subortseva, Alla M. Kovrigina, EK Egorova, A O Abdullaev, Andrey Sudarikov, EI Pustovaya, E A Gilyazitdinova, T I Kolosheinova, A L Melikyan

Publikováno v: Kliničeskaâ onkogematologiâ, Vol 11, Iss 3, Pp 252-258 (2018)

Hydroxycarbamide is an antitumor agent mainly used for treatment of Ph-negative myeloproliferative disorders and sickle cell disease. The development of skin ulcers is a rare but serious adverse event in long-term antitumor therapy. Hydroxycarbamide-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3837c20e602b0007183a1c7306c458ed
https://doi.org/10.21320/2500-2139-2018-11-3-252-258

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání